Lexington, MA, September 18, 2023 –(PR.com)– Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, marks a significant turning point in its history as the company announces the retirement of its founder, Martin Cannon. Simultaneously, the Hemanext Board of Directors has appointed Andrew Dunham, the current Chief Technology Officer of Hemanext, to serve as Chief Executive Officer (CEO). These announcements come as the company proudly reveals the successful close of the B1 funding round totaling $25M, demonstrating strong investor support for its innovative technologies and commitment to enhancing patient care.

Martin Cannon, the visionary leader who founded Hemanext in 2008 with support from a National Institutes of Health (NIH) grant, leaves an enduring legacy. His exceptional foresight in recognizing the potential for enhancing red blood cell (RBC) quality, at a time when our understanding…